News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Adam Cohen, MD

Articles by Adam Cohen, MD

Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.

What Is Cevostamab’s Mechanism of Action in Multiple Myeloma?

ByAdam Cohen, MD

December 14th 2025

Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.

Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.

Treatment Before Cevostamab May Not Affect Outcomes as Much in Multiple Myeloma

ByAdam Cohen, MD

December 13th 2025

Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.

Latest Updated Articles

What Is Cevostamab’s Mechanism of Action in Multiple Myeloma?
December 14th 2025
Treatment Before Cevostamab May Not Affect Outcomes as Much in Multiple Myeloma
December 13th 2025

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)